Buspirone to improve compliance in venlafaxine-induced movement disorder [1]

International Journal of Neuropsychopharmacology

Volumn 7, Issue 4, 2004, Pages 523-524

  Pavlovic, Zoran M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; MAPROTILINE; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; AKATHISIA; BRUXISM; CASE REPORT; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LETTER; MAJOR DEPRESSION; MOTOR DYSFUNCTION; PARKINSONISM; PATIENT COMPLIANCE; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUSPIRONE; COMPLIANCE; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MIDDLE AGED; SEROTONIN AGONISTS;

EID: 10644276322     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145704004638     Document Type: Letter

References (6)

1. Bostwick JM, Jaffe MS (1999). Buspirone as an antidote to SSRI-induced bruxism in 4 cases. Journal of Clinical Psychiatry 60, 857-860.
2. Eberle-Wang K, Lucki I, Chesselet MF (1996). A role of the subthalamic nucleus in 5-HT2C-induced oral dyskinesia. Neuroscience 72, 117-128.
3. Gerber PE, Lynd LD (1998). Selective serotonin reuptake inhibitor-induced movement disorders. Annals of Pharmacotherapy 32, 692-698.
4. Leo RJ (1996). Movement disorders associated with serotonin selective reuptake inhibitors. Journal of Clinical Psychiatry 57, 449-454.
5. Mehta A, Eberle-Wang K, Chesselet MF (2001). Increased m-CPP-induced oral dyskinesia after lesion of serotonergic neurons. Pharmacology, Biochemistry and Behavior 68, 347-353.
6. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB (1986). Antidepressant biochemical profile of the novel byclic compound WAY-45,030, an ethyl cyclohexanol derivative. Biochemical Pharmacology 35, 4493-4497.